Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer

Androgen deprivation therapies (ADTs) are important treatments which inhibit androgen-induced prostate cancer (PCa) progression by either preventing androgen biosynthesis (e.g. abiraterone) or by antagonizing androgen receptor (AR) function (e.g. bicalutamide, enzalutamide, darolutamide). A major li...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Anna E., Metzler, Veronika M., Lothion-Roy, Jennifer, Varun, Dhruvika, Woodcock, Corinne L., Haigh, Daisy B., Endeley, Chantelle, Haque, Maria, Toss, Michael S., Alsaleem, Mansour, Persson, Jenny L., Gudas, Lorraine J., Rakha, Emad, Robinson, Brian D., Khani, Francesca, Martin, Laura M., Moyer, Jenna E., Brownlie, Juliette, Madhusudan, Srinivasan, Allegrucci, Cinzia, James, Victoria H., Rutland, Catrin S., Fray, Rupert G., Ntekim, Atara, de Brot, Simone, Mongan, Nigel P., Jeyapalan, Jennie N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575553/
https://www.ncbi.nlm.nih.gov/pubmed/36263323
http://dx.doi.org/10.3389/fendo.2022.1006101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575553/
https://www.ncbi.nlm.nih.gov/pubmed/36263323
http://dx.doi.org/10.3389/fendo.2022.1006101

Ejemplares similares